drugset

drugset / Trial / NCT04983888

Obinutuzumab in Primary FSGS

NCT04983888 ↗

Phase 2 Completed 20 enrolled Mayo Clinic Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria.

Timeline

Start: 2021-11-17
Primary completion: 2025-06-16
Completion: 2025-06-16

Publications

Dossier C, Bonneric S, Baudouin V, Kwon T, Prim B, Cambier A, Couderc A, Moreau C, Deschenes G, Hogan J. Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children. Clin J Am Soc Nephrol. 2023 Dec 1;18(12):1555-1562. doi: 10.2215/CJN.0000000000000288. Epub 2023 Sep 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Obinutuzumab	Monoclonal antibody	1 g	Intravenous

Indications